Alpha 1-antitrypsin deficiency cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
{{ | {{WikiDoc Help Menu}} | ||
{{ | {{WikiDoc Sources}} |
Revision as of 15:32, 1 June 2016
Alpha 1-antitrypsin deficiency Microchapters |
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Alpha 1-antitrypsin deficiency cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency cost-effectiveness of therapy |
FDA on Alpha 1-antitrypsin deficiency cost-effectiveness of therapy |
CDC on Alpha 1-antitrypsin deficiency cost-effectiveness of therapy |
Alpha 1-antitrypsin deficiency cost-effectiveness of therapy in the news |
Blogs on Alpha 1-antitrypsin deficiency cost-effectiveness of therapy |
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: